Sequelae of traveler's diarrhea: Focus on postinfectious irritable bowel syndrome

被引:56
作者
Connor, BA [1 ]
机构
[1] Cornell Univ, New Yorp Presbyterian Hosp, Weill Med Coll, New York Ctr Travel & Trop Med,Div Gastroenterol, New York, NY 10021 USA
关键词
D O I
10.1086/432956
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Traveler's diarrhea is usually an acute, self-limited illness; however, in some patients, enteric symptoms can persist for weeks, months, or years. It has been estimated that up to 3% of patients with traveler's diarrhea have symptoms for > 30 days. The differential diagnosis includes persistent infection, coinfection, temporary postinfection phenomena, or malabsorptive syndromes. Once these possibilities are excluded, and if symptoms persist, a diagnosis of postinfectious irritable bowel syndrome (PI-IBS) becomes more likely. PI-IBS has recently become a topic of considerable clinical and investigative interest, because evidence validating it as a diagnosis and elucidating its pathophysiological mechanisms has accumulated. Epidemiological evidence suggests that PI-IBS is a relatively common sequela of acute gastroenteritis. Experimental evidence suggests that chronic inflammation following acute bacterial infection has a pathophysiological role in the development of PI-IBS. A fuller understanding of these pathophysiological mechanisms will lead to a more directed therapeutic approach and, perhaps, a reevaluation of prophylaxis for traveler's diarrhea as a means of primary prevention of PI-IBS.
引用
收藏
页码:S577 / S586
页数:10
相关论文
共 52 条
[1]   CHRONIC DIARRHEAL ILLNESS IN UNITED-STATES-PEACE-CORPS VOLUNTEERS [J].
ADDISS, DG ;
TAUXE, RV ;
BERNARD, KW .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1990, 19 (01) :217-218
[2]   Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea:: A crossover, randomized trial [J].
Attar, A ;
Flourié, B ;
Rambaud, JC ;
Franchisseur, C ;
Ruszniewski, P ;
Bouhnik, Y .
GASTROENTEROLOGY, 1999, 117 (04) :794-797
[3]  
Barber R, 1997, BRIT MED J, V314, P1903
[4]  
BLUMBERG RS, 1993, NEW ENGL J MED, V329, P561
[5]  
Camilleri M, 1999, ALIMENT PHARM THERAP, V13, P1149
[6]  
CHAUDHARY NA, 1962, Q J MED, V31, P307
[7]  
CONNOR BA, 2004, TRAVEL MED, P503
[8]  
COOK GC, 1984, LANCET, V1, P721
[9]   Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms [J].
Di Stefano, M ;
Strocchi, A ;
Malservisi, S ;
Veneto, G ;
Ferrieri, A ;
Corazza, GR .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (08) :1001-1008
[10]  
Di Stefano M, 2000, ALIMENT PHARM THERAP, V14, P551